INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 94 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 34.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $18,000 | +5.9% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $17,000 | -10.5% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $19,000 | -9.5% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $21,000 | -41.7% | 20,000 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $36,000 | -5.3% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $38,000 | +58.3% | 20,000 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $24,000 | -55.6% | 20,000 | 0.0% | 0.00% | -60.0% |
| Q3 2018 | $54,000 | +42.1% | 20,000 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $38,000 | -9.5% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $42,000 | +2.4% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $41,000 | -24.1% | 20,000 | -50.0% | 0.00% | -33.3% |
| Q3 2017 | $54,000 | -12.9% | 40,000 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $62,000 | -52.3% | 40,000 | 0.0% | 0.01% | -50.0% |
| Q1 2017 | $130,000 | +140.7% | 40,000 | 0.0% | 0.01% | +140.0% |
| Q4 2016 | $54,000 | -12.9% | 40,000 | 0.0% | 0.01% | +25.0% |
| Q3 2016 | $62,000 | +14.8% | 40,000 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $54,000 | -74.3% | 40,000 | 0.0% | 0.00% | -75.0% |
| Q1 2016 | $210,000 | -33.1% | 40,000 | 0.0% | 0.02% | -33.3% |
| Q4 2015 | $314,000 | -7.1% | 40,000 | 0.0% | 0.02% | 0.0% |
| Q3 2015 | $338,000 | -22.8% | 40,000 | 0.0% | 0.02% | -33.3% |
| Q2 2015 | $438,000 | -21.8% | 40,000 | 0.0% | 0.04% | -20.0% |
| Q1 2015 | $560,000 | -17.2% | 40,000 | 0.0% | 0.04% | -15.1% |
| Q4 2014 | $676,000 | +26.1% | 40,000 | 0.0% | 0.05% | +20.5% |
| Q3 2014 | $536,000 | +5.1% | 40,000 | 0.0% | 0.04% | +4.8% |
| Q2 2014 | $510,000 | +7.1% | 40,000 | 0.0% | 0.04% | 0.0% |
| Q1 2014 | $476,000 | -13.8% | 40,000 | 0.0% | 0.04% | -22.2% |
| Q4 2013 | $552,000 | -20.9% | 40,000 | 0.0% | 0.05% | -15.6% |
| Q3 2013 | $698,000 | +7.7% | 40,000 | 0.0% | 0.06% | +10.3% |
| Q2 2013 | $648,000 | – | 40,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |